Recombinetics

Makana Therapeutics is engaged in the development of genetically modified swine that exhibit reduced xenoantigen expression, facilitating the potential for human transplantation of cells, tissues, and organs from these animals. Founded in 2009 and based in Miami, Florida, the company aims to address the organ shortage crisis by commercializing a pipeline of transplantable materials, including those for the kidney, heart, lung, liver, blood, and pancreatic islets. By focusing on simplified genetics, optimized pig cloning techniques, and careful patient selection, Makana Therapeutics seeks to streamline product development and enhance the safety and efficacy of its transplantable offerings.